Eligi
Med
Ensayos clinicos
Suscripcion
Sobre EligiMed
Ensayos Clinicos de Obstetricia y Ginecologia | EligiMed
Ensayos clinicos
380 ensayos encontrados
Activo, no recluta
Fase 3
ClinicalTrials.gov
Phase III Study of Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive, First-line Metastatic Breast Cancer (DESTINY-Breast09)
INTERVENTIONAL
Inicio: 26 de abr de 2021
ID: NCT04784715
Reclutando
Fase 2
ClinicalTrials.gov
A Phase II, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Neoadjuvant Treatment With Inavolisib Combinations in Patients With Untreated, Early-stage, PIK3CA-Mutated Breast Cancer
INTERVENTIONAL
Inicio: 9 de sept de 2025
ID: NCT07054190
Completado
Fase 2
ClinicalTrials.gov
A Randomized Open-Label, Phase II Study of Lapatinib-capecitabine or Lapatinib-vinorelbine or Lapatinib/Gemcitabine in Subjects With Her2/Neu Amplified Metastatic Breast Cancer Patients Progression After Taxanes Treatment
INTERVENTIONAL
Inicio: 1 de nov de 2009
ID: NCT01050322
Completado
Fase 3
ClinicalTrials.gov
An Open-label Study to Evaluate the Safety and Effect on Disease Progression and Overall Survival of Avastin Plus Taxane-based Chemotherapy in Patients With Locally Recurrent or Metastatic Breast Cancer
INTERVENTIONAL
Inicio: 1 de sept de 2006
ID: NCT00448591
Completado
Fase 3
ClinicalTrials.gov
A Two-Cohort, Open-Label, Multicenter Study of Trastuzumab Emtansine (T-DM1) in HER2-Positive Locally Advanced or Metastatic Breast Cancer Patients Who Have Received Prior Anti-HER2 and Chemotherapy-Based Treatment
INTERVENTIONAL
Inicio: 27 de nov de 2012
ID: NCT01702571
Desconocido
ClinicalTrials.gov
Effectiveness of a Decision Support System in Improving the Diagnosis and Screening Rate of Breast Cancer
INTERVENTIONAL
Inicio: 1 de nov de 2009
ID: NCT01336257
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose Tumors Do Express PD-L1
INTERVENTIONAL
Inicio: 20 de jul de 2022
ID: NCT05382299
Completado
Fase 2
ClinicalTrials.gov
A Phase 1b/2, Multicenter, Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors With FGFR2b Overexpression (FORTITUDE-301)
INTERVENTIONAL
Inicio: 23 de sept de 2022
ID: NCT05325866
Reclutando
Fase 3
ClinicalTrials.gov
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo As Maintenance Therapy After First Line Induction Therapy in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
INTERVENTIONAL
Inicio: 8 de sept de 2023
ID: NCT05894239
Completado
ClinicalTrials.gov
Evaluation of an mHealth Intervention Using an Automated Text Message (SMS) Invitation System to Increase Participation in Mammography Screening Among Women Aged 50-69 Years in the Province of Santa Fe, Argentina
INTERVENTIONAL
Inicio: 5 de dic de 2021
ID: NCT06500936
Reclutando
Fase 2
ClinicalTrials.gov
A Phase I/II Randomized Multi-Cohort Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 in Combination With Anti-Cancer Agents in Participants With Advanced Solid Tumors
INTERVENTIONAL
Inicio: 4 de mar de 2025
ID: NCT06796907
Completado
Fase 3
ClinicalTrials.gov
Pivotal Study in Breast Cancer Patients Investigating Efficacy and Safety of LA-EP2006 and Neulasta®
INTERVENTIONAL
Inicio: 1 de mar de 2012
ID: NCT01516736
Reclutando
Fase 3
ClinicalTrials.gov
An Open-label, Randomized Phase 3 Study of MK-2870 as a Single Agent and in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer
INTERVENTIONAL
Inicio: 14 de abr de 2024
ID: NCT06312176
Completado
Fase 3
ClinicalTrials.gov
A Multicenter Phase III Randomized Trial Comparing Docetaxel in Combination With Doxorubicin and Cyclophosphamide Versus Doxorubicin and Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment of Operable Breast Cancer HER2neu Negative Patients With Positive Axillary Lymph Nodes
INTERVENTIONAL
Inicio: 1 de nov de 2001
ID: NCT00312208
Activo, no recluta
ClinicalTrials.gov
A Multicenter, Prospective, Non-selection Study for Endometrial Receptivity Analysis Test in Patients With Previous Implantation Failures
OBSERVATIONAL
Inicio: 16 de ene de 2024
ID: NCT06097559
Terminado
Fase 3
ClinicalTrials.gov
A Phase III Randomized, Double Blind, Placebo Controlled Study of BKM120 With Fulvestrant, in Postmenopausal Women With Hormone Receptor-positive HER2-negative AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTOR Inhibitor Based Treatment
INTERVENTIONAL
Inicio: 3 de oct de 2012
ID: NCT01633060
Completado
Fase 3
ClinicalTrials.gov
LUX-Breast 1; An Open Label, Randomised Phase III Trial of BIBW 2992 and Vinorelbine Versus Trastuzumab and Vinorelbine in Patients With Metastatic HER2-overexpressing Breast Cancer Failing One Prior Trastuzumab Treatment
INTERVENTIONAL
Inicio: 22 de jun de 2010
ID: NCT01125566
Completado
ClinicalTrials.gov
Treatment Patterns And Clinical Outcomes Among Patients in Latin America Receiving First Line Palbociclib Combinations For HORMONE RECEPTOR POSITIVE/ HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE (HR+/HER2-) Advanced/Metastatic Breast Cancer In Real World Settings
OBSERVATIONAL
Inicio: 15 de may de 2019
ID: NCT05155566
Completado
ClinicalTrials.gov
Laparoscopic Treatment for Appendicitis During Pregnancy: Retrospective Cohort Study
OBSERVATIONAL
Inicio: 1 de sept de 2005
ID: NCT04753502
Activo, no recluta
Fase 3
ClinicalTrials.gov
A Randomised, Double-blind, Parallel Group, Placebo-controlled Multi-centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients With gBRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy
INTERVENTIONAL
Inicio: 22 de abr de 2014
ID: NCT02032823
Anterior
1
...
18
19
Filtros